Accepted for/Published in: JMIR Formative Research
Date Submitted: Aug 15, 2022
Date Accepted: Dec 27, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Improvements in Glycemic Control and Depressive Symptoms among adults with Type 2 Diabetes: A Retrospective Study
ABSTRACT
Background:
The prevalence of diabetes remains high, with traditional lifestyle interventions demonstrating limited success in improving diabetes-related outcomes, particularly among individuals with diabetes related mental health comorbidities. Digital health interventions provide the ability to ease the sustained and rigorous self-management needs associated with diabetes care and treatment. Current interventions though, are plagued by small sample sizes, underpowered pilot studies, and immense heterogeneity in program intervention, duration, and measured outcomes.
Objective:
Therefore, this work aimed to evaluate the effectiveness of an mHealth diabetes management program on measures of glycemic control in a high risk population with type 2 diabetes (hemoglobin A1c (HbA1c) ≥ 8.0%), utilizing a sample of 1,128 participants who provided baseline and follow-up data. Sustainability of this change in glycemic control was examined in a subset of participants (n = 455) at 6-months and 1- year following program enrollment. A secondary analysis examined changes in glycemic control among a subset of participants with self-reported mild to moderate depression at baseline.
Methods:
This study utilized a single-arm, retrospective design. Participants were enrolled in the Vida Health Diabetes Management Program. This app-based intervention utilized one-on-one remote sessions with a Health Coach, Registered Dietitian Nutritionist, and/or a Certified Diabetes Care and Education Specialist and structured lessons and tools related to diabetes management and self-care. Participants provided baseline (-365 to 21 days of program enrollment) HbA1c values as well as follow-up (at least 90 days following program enrollment). Paired t-tests were used to evaluate changes in HbA1c between baseline and follow-up time points. The Patient Health Questionnaire (PHQ-8) and the Generalized Anxiety Disorder Scale (GAD-7) were utilized to assess self-reported depressive and anxiety symptoms, respectively. Paired t-tests and linear regression modeling accounting for pertinent covariates were used to evaluate changes in mental health symptom acuity and their relationship with changes in glycemic control.
Results:
We observed a significant decrease in HbA1c of -1.35 points between baseline (mean: 9.84, SD: 1.64) and follow-up (mean: 8.48, SD: 1.77; t=22.56; P<0.001) among this large, high-risk sample. This decrease was sustained up to one year following program enrollment. Additionally, a significant relationship between improvements in depressive symptom acuity and improvements in HbA1c was observed (β=–0.74, P=0.03).
Conclusions:
The present study demonstrates clinically meaningful improvements in glycemic control among participants enrolled in the Vida Health Diabetes Management Program. Additionally, this work presents the one of the largest studied samples of participants enrolled in a digital health diabetes management program to date. Clinical Trial: n/a
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.